Long-term outcomes of stent grafts for abdominal aortic aneurysm repair
Follows adults with abdominal aortic aneurysm treated with GORE EXCLUDER devices for 10 years.
Key facts
- Who runs it
- W.L.Gore & Associates
- Where
- Auckland and Hamilton, New ZealandSee the 2 sitesAlso in 12 other countries, 72 sites
- Trial code
- Registry title
- Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
- Status
- Recruiting
- People taking part
- 2,000 people, planned
- Started
- 7 May 2024
- Expected to end
- 30 Sept 2042
- Type of study
- Observational, 2 groups
- Record updated
- 12 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with an abdominal aortic aneurysm (a bulge in the main belly artery). They have been or will be treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis in routine care. Follow-up lasts 10 years.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- Abdominal aortic aneurysm treated through the blood vessels (endovascular repair).
- Earlier treatment
- People must have been treated, or be planned for treatment, with one of the registry devices (EXCC Device or IBE Device).
Main reasons for not taking part
- People unlikely to come to the usual follow-up visits set by the site.
- People excluded by local law.
- People in, or planning to join, another drug or device study within 12 months of joining.
- People in another Together Registry module.
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Patient or legally authorized representative (LAR) provides written authorization and/or consent per institution and geographical requirements
- Patient has been or is intended to be treated with an eligible registry device
- Patient is age ≥ 18 years at time of informed consent signature
Who cannot take part
- Patient is currently enrolled in or plans to enroll in any concurrent drug and/or device study within 12 months of Together Registry enrollment. Subjects cannot be enrolled in another Together Registry module protocol
- Patient who is, at the time of consent, unlikely to be available for standard of care (SOC) follow-up visits as defined by the site's guidelines and procedures
- Patient with exclusion criteria required by local law
Where in New Zealand
Also in 12 other countries, 72 sites
- Auckland District Health Board Charitable TrustAuckland, New ZealandContact: Cindy CorneTaking people
- Clinical Trials New Zealand Limited - Waikato HospitalHamilton, New ZealandContact: Lenka FeisstTaking people
About the trial
What the trial wants to find out
A prospective, observational post-market registry collecting outcomes through a 10-year post procedure follow-up for patients treated with the GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device) or the GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device) as a part of routine clinical practice.
The 2 groups in the trial
- GORE® EXCLUDER® Conformable AAA Endoprosthesis (EXCC Device)
Patients treated with the EXCC Device
- GORE® EXCLUDER® Iliac Branch Endoprosthesis (IBE Device)
Patients treated with the IBE Device
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of Long Term, Endovascular AAA Intervention Using the GORE® EXCLUDER® Conformable AAA Endoprosthesis or Iliac Branch Endoprosthesis
- Plain-language title
- Long-term outcomes of stent grafts for abdominal aortic aneurysm repairGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 12 November 2026